S-2P + montanide ISA720
S-2P + montanide ISA720 has been studied in 1 paper since 2025: none in people yet, 1 in animals. The research so far is in animals. The newest paper, Oct 3, 2025: “Adjuvant-dependent protection of SARS-CoV-2 spike vaccines: comparative immunogenicity of human-applicable formulations”.
1 paper studies it2 findingsUpdated
See all 1 papers on S-2P + montanide ISA720
At a glance
The findings reach mice, none yet in people. 1 lab in 2 countries.
None of its findings points the other way.
- 1 lab in 2 countries
- Funders: Ministry of Science and Technology of the People's Republic of China and 1 more
- Animals1
What did studies of S-2P + montanide ISA720 find?
2Studies of S-2P + montanide ISA720 measured 2 outcomes; the most studied are death following SARS-CoV-2 challenge (1 study) and humoral immunity (1).
Death following SARS-CoV-2 challenge
downin mice1
1 study
Death following SARS-CoV-2 challenge
downin mice1
S-2P + montanide ISA720 protects against death following SARS-CoV-2 challenge in mice (Lethal challenge with ancestral SARS-CoV-2 or Omicron BA.5 and BF.7) (Complete protection).
“Immunization with S-2P:ISA720 conferred complete protection against lethal challenge with the ancestral virus as well as Omicron subvariants BA.5 and BF.7.”
AnimalsLethal challenge with ancestral SARS-CoV-2 or Omicron BA.5 and BF.7
Journal of virology
humoral immunity
upin mice1
1 study
humoral immunity
upin mice1
S-2P + montanide ISA720 increases humoral immunity in mice.
“Both S-2P:ISA720 and S-2P:ISA51 elicited potent humoral immunity, including cross-neutralizing antibodies against Omicron variants”
Animals
Journal of virology